Introduction &
In men, the risk of developing coronary artery disease and hypertension is much higher than in premenopausal women ( Messerli et al., 1987 ; Khaw et al., 1988 ) . However, cardiovascular protection during the reproductive age is lost after menopause, and is recovered in postmenopausal women who receive estrogen replacement therapy ( Stampfer et al., 1991 ) . This has led to supposition that estrogens are benefi cial and androgens are detrimental to the cardiovascular system. There is now a plethora of evidence that estrogens may play an important cardiovascular protective role not only by means of long-term systemic effects, like those on serum lipid profi le, but also by means of direct effects of vascular structure and function, such as inhibition of vascular growth modulation of vascular tone ( Simonchini and Genazzani, 2003 ; Cho et al., 2003 ) . Of the effects previously studied, the vasodilating effect induced by estrogens has been well-documented. The mechanism of action of estrogens appears to involve genomic and non-genomic mechanisms that cause increase and release of vasodilatory agents such as nitric oxide (NO) and prostacyclin, adenosine, cAMP
Abstract &
The increased incidence of cardiovascular disease in man compared with premenopausal women suggests an unfavourable effect of male sex hormone testosterone on the cardiovascular system. However, numerous clinical and epidemiological studies reported a controversial relationship between testosterone and cardiovascular disease. Furthermore, an increasing amount of evidence indicate that testosterone can exert acute vasorelaxing effects, via non-genomic and cGMP ( Belfort et On the other hand, testosterone has classically been considered to exert an unfavourable effect upon the cardiovascular system. However, numerous clinical and epidemiological studies reported a controversial relationship between testosterone and cardiovascular disease. For example, low circulating testosterone levels in men are positively correlated with numerous risk factors for coronary heart disease ( English et al., 1997 and 2000a ) . Evidence also supports a benefi cial effect of testosterone on the blood lipid profi le and against atheroma formation ( English et al., 1997 ; Duell et al., 1990 ; Khaw et al., 1991 ; Hromadowa et al., 1991a and b ; Alexandersen et al., 1999 ). Furthermore, acute intracoronary or intravenous infusion of testosterone also provides rapid improvements in myocardial ischemia ( Rosano et al., 1999 ; Webb et al., 1999a ) . Finally, testosterone replacement therapy improves myocardial ischemia in patients with coronary artery disease, an effect presumably due to testosterone -induced coronary vasodilamechanisms. These effects involve primarily the vascular smooth muscle, without requiring the presence of endothelium, although an endothelial contribution is apparent in some studies. To date, the mechanism behind the vasodilatory action of testosterone is still under debate and might be through either activation of K + channels or blockade of Ca 2 + channels in vascular muscle cells. The purpose of this article is to review the evidence regarding the vasodilating effect of testosterone as well as its mechanism of action.
tation ( English et al., 2000b ) . Previous animal studies have demonstrated that testosterone acts as a direct coronary vasodilator in a variety of species, including rabbit, dog, pig, and rat, both in vivo ( Chou et al., 1996 ) 
Involvement of aromatization
Potential conversion of testosterone to estrogen is another important concept to be addressed. In this respect, previous studies have demonstrated that inhibition of aromatase activity or estrogen receptor antagonism had no effect of testosteroneinduced vasodilation ( Yue et al., 1995 ; Tep-areenan et al., 2002 ) . Moreover, similar vasodilatation to testosterone was triggered by non-aromatizable dihydrotestosterone ( Deenadayalu et al., 2001 ). In our laboratory, we used tamoxifen, an estrogen receptor antagonist and protein kinase C inhibitor, and letrozole, a non-steroidal aromatase inhibitor, to test the role of aromatisation in testosterone-induced relaxation in IMA.
While tamoxifen inhibited testosterone-induced relaxation, letrozole had no effect ( Gul et al., 2004 ) . This suggested that aromatisation did not occur in human IMA, thus estrogen did not contribute on testosterone-induced relaxation. Fig. 1 ).
Involvement of endogenous vasodilators

Contradictory effects of testosterone on potassium channels
There is a complex-mixture of vessel-type dependent mechanisms reported in previous studies about the type of the K + channel involved in the vasodilatory action of testosterone. In rabbit, dog and pig coronary conduit arteries, testosterone acts via BK Ca and K V channel opening action, however testosteroneinduced vasodilation occurs via K ATP channel opening action in dog coronary resistance arteries ( Yue et al., 1995 ; Chou et al., 1996 ; Deenadayalu et al., 2001 ). Accordingly, testosterone acts via BK Ca channel opening action in an human conduit artery, the IMA ( Yildiz et al., 2005a ). However, RA shows a resistance vessel characteristics as elastomuscular wall structure and a small diameter, and testosterone -induced vasodilation occurs via K ATP channel opening action in RA similar to resistance arteries (unpublished observations). Therefore, it may be suggested that testosterone preferentially stimulates the K V and K Ca channels in large conductance vessels, and the K ATP channel in small resistance vessels. In fact, there are some differences in the vascular reactivity between large conductance and small resistance arteries Yokoshiki and Sperelakis, 2003 . For example, it was reported that adenosine, a metabolic regulator of coronary blood fl ow (probably via activating K ATP channels and inhibiting L-type Ca 2 + current (t), preferentially blocked the action potential in the small coronary artery, but had no effect on the action potential Review in the large coronary artery ( Harder et al., 1979 ) . Likewise, the coronary dilating actions levcromakalim, of a K ATP channel opening drug, were heterogeneous, and it was more sensitive in small resistant coronary arteries ( Sato et al., 1994 ) . It was also reported that the resting tone of large coronary conductance vessels was little affected by glibenclamide ( Shimizu et al., 2000 ) , whereas that of small resistance vessels was affected. Hence, the tone of the small vessels is likely to be regulated by the glibenclamidesensitive K ATP channel ( Yokoshiki et al., 1997 ) . Another important fi nding is that testosterone relaxes human internal mammary and radial arteries but it has no vasodilatory effect on human umbilical arteries (HUA) ( Yildiz et al., 2005a ) . HUA is unique, since it shows a conductance vessel characteristics as elastic wall structure and it has a small diameter. Functional K v and BK Ca channels are present in HUA ( Yildiz et al., 2006a ) . However, this artery seems to lack the non-genomic signalling pathway involved in testosterone-induced vasodilation.
Potential factors infl uencing testosterone responses
An important point of the previous studies which should be addressed was that high concentrations of testosterone (in the micromolar range) were required to elicit vasodilation. Most of these studies were carried out in isolated vessel preparations, therefore the effects of testosterone might occur only at supraphysiological concentrations. There may be a concentration gradient from the perfusate down to the cell membrane as a result of impaired delivery of the testosterone molecule or binding to various proteins. There may be a consequence of access to smooth muscle ion channels; this could be restricted in more intact preparations lacking their natural blood supply as the lipophilic androgen would need to cross some barriers before reaching its presumed target on smooth muscle cells ( Hall et al. 2006 ) . Another point of the previous studies which should be looked up was the latency for the vasodilating effect of testosterone. In most of the mechanistic studies cited in this review, free testosterone analogues were used, and the vasodilatory action of testosterone was rapid, occuring within minutes. As mentioned above, the covalent linkage of testosterone analogues to a macromolecule, such as albumin, has no effect upon the timescale and magnitude of the vasodilatory response to testosterone ( English et al., 2000d ; Ding and Stallone, 2001 ). Therefore, the conjugation of testosterone to albumin eliminates the permeability of testosterone to the cell membrane, and thereby, these fi ndings again suggest a non-genomic action. 
Variability of testosterone -induced vasodilatory responses
An interesting fi nding in our observations was the marked variability of responses to testosterone in various subjects in IMA ( Yildiz et al., 2005a ) . We have recently investigated the relationship of this variability with cardiovascular risk factors ( Yildiz et al., 2005b ) . Cumulative relaxations to testosterone after precontraction with KCl have been examined in IMA segments from patients with identifi ed cardiovascular risk factors such as hypercholesterolemia, diabetes, hypertension, smoking, age, gender, body mass index (BMI), and number of occluded vessels. Testosterone responses were signifi cantly diminished in subjects with 3 compared with 1 risk factor. Hypercholesterolemia has independently infl uenced testosterone responses by significantly decreasing its maximum, and smoking has signifi cantly decreased the sensitivity to testosterone. In our study, aging is one of the factors related to diminished testosterone responses. In accordance, English et al. (2000b) have also demonstrated that aging reduces the testosterone -induced relaxation in coronary arteries from male Wistar rats in vitro. We have concluded that the variability observed in testosterone-induced vascular relaxations may in part be related to differences in risk factors present among the individuals studied ( Yildiz et al., 2005b ) . ( Yildiz et al., 2005a ) . We have tried testosterone on UA and observed no response. Previously, Fausett et al also reported that testosterone had no relaxant effect on human umbilical artery ( 1999 ). Obviously, additional studies in human arteries would be of interest to make clear the mechanism of vasodilatory effect of testosterone in different vascular beds. Taken together, these fi ndings provide evidence for the marked vasodilating effect induced by testosterone. Further studies, especially in different human vascular preparations and with cellular patch-clamp techniques, are essential to understand the exact mechanism of the effect testosterone and to fully realise the therapeutic potential of testosterone therapy in male patients with coronary artery disease.
Clinical relevance and future research
